Palatin Technologies Inc (PTN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palatin Technologies Inc (PTN) has a cash flow conversion efficiency ratio of 0.838x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.35 Million) by net assets ($-6.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Palatin Technologies Inc worth for the company's overall valuation and market capitalisation.
Palatin Technologies Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Palatin Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Palatin Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palatin Technologies Inc ranked by their cash flow conversion efficiency. Explore Palatin Technologies Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XMReality AB
ST:XMR
|
0.069x |
|
Seeing Machines Limited
LSE:SEE
|
-0.731x |
|
Jadestone Energy Inc
LSE:JSE
|
-0.550x |
|
BLACK PEARL ZY-10
F:7ZX
|
-0.011x |
|
Quest PharmaTech Inc
V:QPT
|
-0.002x |
|
Beam Communications Holdings Ltd
AU:BCC
|
0.476x |
|
Hydrotek Public Company Limited
BK:HYDRO
|
-0.054x |
|
JPmorgan US Smaller Companies Investment Trust PLC
LSE:JUSC
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Palatin Technologies Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Palatin Technologies Inc from 1996 to 2024. View PTN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $-111.50K | $-31.46 Million | 282.173x | +233.12% |
| 2023-06-30 | $134.07K | $-28.42 Million | -211.967x | -11423.83% |
| 2022-06-30 | $16.27 Million | $-29.92 Million | -1.839x | -303.25% |
| 2021-06-30 | $49.65 Million | $-22.65 Million | -0.456x | -188.49% |
| 2020-06-30 | $80.17 Million | $41.33 Million | 0.515x | +337.94% |
| 2019-06-30 | $100.55 Million | $-21.78 Million | -0.217x | -443.00% |
| 2018-06-30 | $26.96 Million | $1.70 Million | 0.063x | +102.53% |
| 2017-06-30 | $-5.16 Million | $12.88 Million | -2.494x | -192.61% |
| 2016-06-30 | $-17.59 Million | $-47.36 Million | 2.693x | +346.07% |
| 2015-06-30 | $12.20 Million | $-13.36 Million | -1.095x | +12.23% |
| 2014-06-30 | $9.79 Million | $-12.21 Million | -1.247x | -109.95% |
| 2013-06-30 | $22.98 Million | $-13.65 Million | -0.594x | +92.98% |
| 2012-06-30 | $1.83 Million | $-15.49 Million | -8.459x | -1295.05% |
| 2011-06-30 | $18.19 Million | $-11.03 Million | -0.606x | +1.39% |
| 2010-06-30 | $9.32 Million | $-5.73 Million | -0.615x | +62.57% |
| 2009-06-30 | $3.31 Million | $-5.44 Million | -1.643x | +47.69% |
| 2008-06-30 | $6.55 Million | $-20.58 Million | -3.141x | -163.94% |
| 2007-06-30 | $18.53 Million | $-22.05 Million | -1.190x | +7.13% |
| 2006-06-30 | $18.30 Million | $-23.45 Million | -1.281x | -133.44% |
| 2005-06-30 | $9.23 Million | $-5.06 Million | -0.549x | +55.18% |
| 2004-06-30 | $19.39 Million | $-23.74 Million | -1.225x | -14.86% |
| 2003-06-30 | $18.66 Million | $-19.89 Million | -1.066x | +29.55% |
| 2002-06-30 | $8.69 Million | $-13.15 Million | -1.513x | -114.75% |
| 2001-06-30 | $11.92 Million | $-8.40 Million | -0.705x | +43.02% |
| 2000-06-30 | $6.91 Million | $-8.54 Million | -1.237x | +96.43% |
| 1999-06-30 | $300.00K | $-10.40 Million | -34.667x | -1492.79% |
| 1998-06-30 | $3.40 Million | $-7.40 Million | -2.176x | -420.23% |
| 1997-06-30 | $9.80 Million | $-4.10 Million | -0.418x | +56.18% |
| 1996-06-30 | $2.84 Million | $-2.71 Million | -0.955x | -- |
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more